Render Target: STATIC
Render Timestamp: 2024-11-01T09:51:00.026Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-08-01 15:28:58.003
Product last modified at: 2024-05-30T07:04:57.863Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Annexin A6 Antibody #29015

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 72
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Annexin A6 Antibody recognizes endogenous levels of total annexin A6 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr645 of human annexin A6 protein. Antibodies are purified by peptide affinity chromatography.

    Background

    Annexin A6 (ANXA6) belongs to the highly conserved annexin family of proteins characterized by their calcium (Ca2+)-dependent binding to phospholipids (1-3). The protein is highly expressed in most tissues and is predominantly located at the plasma membrane and the endosomal compartment, where it regulates cell migration and endosome trafficking by organizing membrane domains, interacting with signaling complexes, and forming transient membrane-actin interactions upon Ca2+ stimulation (3). It also mediates intracellular cholesterol homeostasis (3,4). Annexin A6 is frequently upregulated in extracellular vesicles (EVs) of the tumor microenvironment after chemotherapy or tyrosine kinase inhibitor treatment. These EVs have been shown to promote resistance and metastasis in multiple cancer types, such as lung cancer, breast cancer, and pancreatic duct adenocarcinoma (5-7). Annexin A6, in these EVs, enhances the stability of membrane-associated RTKs, such as EGFR, and promotes cancer cell motility, stemness, and autophagy (2,7-9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.